Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference

BOULDER, Colo., Sept. 24, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the NewsMakers in the Biotech Industry Conference.  The public is welcome to participate in the conference through webcasts on the Array BioPharma website:  www.arraybiopharma.com.   

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.   Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.  For more information on Array, please go to www.arraybiopharma.com.

CONTACT: Tricia Haugeto
Array BioPharma Inc.
303-386-1193
thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.

RELATED LINKS
http://www.arraybiopharma.com